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ABSTRACT
The angiogenic inducer CCN1 (Cysteine-rich 61, CYR61) is differentially 
activated in metastatic breast carcinomas. However, little is known about the precise 
mechanisms that underlie the pro-metastatic actions of CCN1. Here, we investigated 
the impact of CCN1 expression on fatty acid synthase (FASN), a metabolic oncogene 
thought to provide cancer cells with proliferative and survival advantages. Forced 
expression of CCN1 in MCF-7 cells robustly up-regulated FASN protein expression 
and also significantly increased FASN gene promoter activity 2- to 3-fold, whereas 
deletion of the sterol response element-binding protein (SREBP) binding site in 
the FASN promoter completely abrogated CCN1-driven transcriptional activation. 
Pharmacological blockade of MAPK or PI-3’K activation similarly prevented the ability of 
CCN1 to induce FASN gene activation. Pharmacological inhibition of FASN activity with 
the mycotoxin cerulenin or the small compound C75 reversed CCN1-induced acquisition 
of estrogen independence and resistance to hormone therapies such as tamoxifen 
and fulvestrant in anchorage-independent growth assays. This study uncovers FASN-
dependent endogenous lipogenesis as a new mechanism controlling the metastatic 
phenotype promoted by CCN1. Because estrogen independence and progression to a 
metastatic phenotype are hallmarks of therapeutic resistance and mortality in breast 
cancer, this previously unrecognized CCN1-driven lipogenic phenotype represents a 
novel metabolic target to clinically manage metastatic disease progression.
INTRODUCTION
CCN1, also known as CYR61, is an extracellular 
matrix-associated protein [1, 2] belonging to the Cysteine 
rich 61/Connective tissue growth factor/Nephroblastoma 
overexpressed (CCN) gene-family of survival and 
angiogenic regulators, which includes CCN2 (CTGF), 
CCN3 (NOV), CCN4 (WISP-1), CCN5 (WISP-2), and 
CCN6 (WISP-3) [3–10]. Whereas all CCN proteins 
have been shown to mediate functions as diverse as 
cell proliferation, migration, adhesion, differentiation, 
and extracellular matrix formation, CCN1 is unique 
among CCN proteins because of its ability to regulate 
more complex processes, such as angiogenesis and 
tumorigenesis [11–19].
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CCN1 is overexpressed in about 30% of triple-
negative breast carcinomas (TNBC) [14, 15]. Although 
TNBC is clearly defined based upon immunohistological 
criteria (estrogen receptor-negative, progesterone 
receptor-negative, and HER2-negative), it remains a 
biologically heterogeneous disease encompassing a 
number of intrinsic molecular subtypes, most frequently 
basal-like and claudin-low [20–22]. Resistance of TNBC 
to standard therapies drastically limits the available 
options for previously treated patients with metastatic 
TNBC and there is currently no preferred standard 
chemotherapy. Not surprisingly, TNBC accounts for a 
disproportionate number of metastatic disease cases and 
breast cancer deaths [23–25].
CCN1 expression strongly correlates with known 
markers for invasiveness, and associates with the ability 
of breast cancer cells to invade in vitro and metastasize 
in vivo [14–16]. Indeed, a significant correlation exists 
between elevated levels of CCN1 and an advanced stage 
of the primary tumor and lymph node involvement at the 
time of surgery [14, 26, 27]. We previously demonstrated 
that CCN1 is an important regulator of the vascular 
compartment in breast cancer, with strong stimulatory 
effects on tumor neovascularization that ultimately 
promotes the progression and metastatic dissemination 
of breast carcinomas [13, 15, 16]. Moreover, CCN1 
expression inversely correlates with estrogen receptor 
expression, response to estradiol, and sensitivity to 
antiestrogen and taxanes-based therapies [18, 28, 
29]. Whereas CCN1 overexpression-driven estrogen 
independence and progression to a metastatic phenotype 
are hallmarks of therapeutic resistance and mortality 
in breast cancer [30–33], the precise mechanisms by 
which CCN1 promotes more aggressive breast cancer 
metastatic phenotypes remain unknown.
Most cancer cells do not use circulating fatty 
acids for energy, but instead endogenously synthesize 
them de novo for growth and survival in the unfavorable 
microenvironment of solid tumors or metastases prior 
to angiogenesis. Indeed, a fatty acid synthase (FASN)-
driven “lipogenic state”, by conferring growth and 
survival advantages, and cross-talking with established 
cancer-controlling signaling pathways, appears to 
necessarily accompany the natural history of most 
human cancers [34–38]. Accordingly, the oncogenic 
nature of FASN overexpression confers tumor 
aggressiveness and poor prognosis in various human 
cancers. However, the role of aberrant expression of key 
lipogenic enzymes such as FASN on metastasis-prone 
phenotypes remains enigmatic [39]. In this work, we 
aimed to examine the influence of the metastasis inducer 
CCN1 on the expression of cancer cell-associated FASN 
as well as the role of FASN activity on some of the key 
metastatic features acquired by CCN1-overexpressing 
breast cancer cells.
RESULTS
CCN1 up-regulates FASN protein expression in 
breast cancer cells
To evaluate the impact of CCN1 on FASN 
expression, we utilized a cellular model of CCN1 
overexpression developed in our laboratory. Estrogen-
dependent MCF-7 breast cancer cells, which naturally 
express very low to undetectable levels of CCN1, were 
transfected with full-length CCN1 cDNA [16, 28] and 
stable cell clones were selected with zeocin. Analysis 
of expanded cell clones by western blotting showed 
that FASN protein expression was markedly higher in 
the CCN1-expressing clones C2-2, C2-9 and C2-6 [28] 
than in empty vector-transfected cells (MCF-7/V) and 
parental MCF-7 cells (Figure 1, left panel). Indeed, CCN1 
overexpression was sufficient to increase steady-state 
FASN protein to levels similar to those found in SKBR3 
cells (data not shown), a naturally occurring FASN-
overexpressing breast cancer cell line.
To assess whether the accumulation of FASN protein 
was uniform in cells overexpressing CCN1, the cellular 
patterns of FASN expression were assessed by microscopy 
(Figure 1, right panel). Although direct quantitative 
interpretation of indirect immunofluorescence is not 
possible, it was evident that cytoplasmic accumulation of 
FASN was higher in CCN1-overexpressing clones than in 
MCF-7/V cells. The difference in FASN intensity between 
CCN1-overexpressing clones and MCF-7/V cells was 
manifest and highly reproducible. These results reveal that 
CCN1 overexpression leads to up-regulation of cancer-
associated FASN.
To confirm that the ability of CCN1 to regulate 
FASN was independent of the up-stream CCN1 activator 
HRG, we evaluated FASN protein expression after 
blockade of CCN1 gene expression in MCF-7 cells 
engineered to overexpress HRG (MCF/T7 cells) [28]. 
FASN expression in MCF-7/T7 cells was similar to 
that found in the CCN1-overexpressing clones C2-2 
and C2-9 (Figure 2, left) Moreover, FASN expression 
was lower in cell lysates from antisense CCN1 clones 
T7/CCN1-AS2, T7/CCN1-AS4, T7/CCN1-AS6, and 
T7/CCN1-AS7 than in MCF-7/T7 cells (Figure 2, 
left). Additionally, in HRG-overexpressing T7/CCN1-
AS cells with intact HRG Æ HER2/3 signaling in the 
absence of CCN1 expression, there was a striking 
correlation between the decrease in FASN expression 
and the reduced secretion of the angiogenic factor 
VEGF165 (Figure 2, right).
These findings reveal that up-regulation of a FASN-
dependent lipogenic phenotype constitutes part of the pro-
metastatic program resulting from CCN1 overexpression 
in breast cancer.
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Figure 1: CCN1-overexpressing MCF-7 breast cancer cells up-regulate FASN protein expression. Left. Cells were cultured 
in IMEM-5% FBS to 75% confluence, washed with PBS and solubilized in lysis buffer. Aliquots (10 μg) of 14 000 × g supernatants were 
fractioned by NuPAGE, transferred to nitrocellulose membranes, probed with an anti-FASN monoclonal antibody, and then re-probed 
with an anti-β-actin antibody. Representative immunoblotting analysis is shown (n = 3). Right. Cells were fixed and labeled with an anti-
FASN monoclonal antibody. Cells were extensively washed, and FASN protein was detected by indirect immunofluorescence using FITC-
conjugated anti-mouse IgG. Cells were counterstained with DAPI and examined with a Zeiss fluorescent microscope. Representative FASN 
immunostaining analysis is shown. Similar results were obtained in three independent experiments.
Figure 2: Blockade of CCN1 down-regulates FASN and VEGF in HRG-overexpressing breast cancer cells. Left. Cells 
were cultured in IMEM-5% FBS to 75% confluence, washed with PBS and solubilized in lysis buffer. Aliquots (10 μg) of 14 000 × g 
supernatants were fractioned by NuPAGE, transferred to nitrocellulose membranes, probed with an anti-FASN monoclonal antibody, and 
then re-probed with an anti-β-actin antibody. Representative immunoblotting analysis is shown (n = 3). Right. Cells were serum-starved 
overnight and then cultured in 0.1% FBS-IMEM for 48 h. Culture supernatants were collected to determine the level of VEGF165 by ELISA, 
which was normalized to the amount of protein in collected cell extracts. Secretion levels of VEGF165 in AS-CCN1 clones were compared 
to those in HRG/CCN1-overexpressing MCF-7/T7 cells. *P < 0.005.
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CCN1 stimulates FASN gene expression in breast 
cancer cells
To determine whether CCN1 overexpression 
affected FASN gene transcription, C2-6 and C2-9 clones 
and MCF-7/V control cells were transfected with a 
reporter construct containing a 178-bp FASN promoter 
fragment harboring all the elements necessary for high-
level expression of FASN, including a complex SREBP-
binding site [40–42]. CCN1 overexpression significantly 
increased luciferase activity 2- to 3-fold relative to 
baseline levels observed in MCF-7/V cells (Figure 3, left). 
To address whether the SREBP-binding sites present in the 
proximal region mediated the effects of CCN1 on FASN 
promoter activation, cells were transiently transfected with 
a FASN promoter in which the SREBP binding region was 
deleted (FASNdelSRE) [40–42]. CCN1-driven stimulation 
of the FASN promoter was completely abolished in the 
absence of the SREBP binding region (Figure 3, right).
Collectively, these results show that CCN1-driven 
stimulation of FASN expression seems to take place, at 
least in part, at the transcriptional level and is mediated 
by cis-acting elements such as the SREBP-binding sites 
present in the proximal FASN gene promoter.
CCN1 stimulates FASN gene expression via PI-
3K and MAPK signaling cascades
Having previously demonstrated that CCN1 
overexpression activates PI-3K/AKT and MEK1/MEK2/
ERK1/ERK2 signaling in MCF-7 cells [16, 28], we 
postulated that CCN1-enhanced FASN expression might 
result from activation of these signaling cascades in 
CCN1-overexpressing cells.
Treatment of C2-9 and C2-6 clones with nontoxic 
concentrations of U0126, a potent inhibitor of the MEK/
ERK MAPK pathway, dose-dependently decreased the 
stimulatory effects of CCN1 on the activity of the FASN 
promoter (Figure 4). Furthermore, treatment with nontoxic 
concentrations of LY294002, a potent cell permeable 
inhibitor of PI-3K, drastically suppressed the activity of 
the FASN promoter in C2-9 and C2-6 cells (Figure 5). 
Additionally, U0126- and LY294002-mediated down-
regulation of FASN protein expression was detected by 
immunocytochemistry (Figure 4 and 5). Immunoblotting 
procedures confirmed the ability of U0126 and LY294002 
to dose-dependently decrease FASN protein expression 
in CCN1-overexpressing breast cancer cells (data not 
shown).
Altogether, these results provide evidence for a 
CCN1-triggered regulatory cascade that actively links 
MAPK and PI-3K transduction upstream of the FASN 
gene, with SREBP-dependent transcriptional regulation 
of the FASN promoter.
Pharmacological inhibition of FASN activity 
reverses CCN1-promoted estrogen independence 
and anti-estrogen resistance
Because MCF-7 cells overexpressing CCN1 are 
estradiol (E2)-independent and acquire an antiestrogen 
resistant phenotype [16, 18], a prevalent clinical 
Figure 3: CCN1 overexpression activates the FASN gene promoter in a SREBP-dependent manner. Cells were transiently 
transfected with a plasmid containing a luciferase reporter gene driven by a 178-bp FASN gene promoter fragment harboring a SREBP-
binding site, flanked by auxiliary NF-Y and Sp-1 sites (left) or with a similar construct in which the SREBP domain was deleted (right). 
Luciferase activity was expressed as relative (fold) change in transcriptional activities of FASN promoter-transfected cells after normalization 
to pRL-CMV activity. Each experimental value represents the mean fold increase (columns) ± S. D. (bars) from at least three separate 
experiments in which triplicate wells were measured. Luciferase activity in CCN1-overexpressing clones was compared to that in MCF-7/V 
control cells. *P < 0.005.
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occurrence in breast cancer progression [30–33], we 
next evaluated whether exacerbated FASN activity might 
serve as part of the molecular program by which CCN1 
promotes an aggressive breast cancer phenotype. To do 
this, we measured anchorage-independent growth as an in 
vitro metric of tumorigenicity.
Neither wild-type (not shown) nor empty vector-
transfected MCF-7/V cells formed colonies in soft-agar 
assays in the absence of estradiol. By contrast, C2-9 and 
C2-6 clones showed a strong anchorage-independent 
capacity to form colonies in the absence of estradiol 
(Figure 6). This estradiol-independent colony forming 
ability was dramatically suppressed in a dose-dependent 
manner with the mycotoxin cerulenin or its semi-synthetic 
derivative C75 (α-methylene-γ-butyrolactone) (Figure 6), 
which are two widely used small-molecule FASN 
inhibitors [43–45].
As expected, estradiol exposure robustly induced 
anchorage-independent growth of MCF-7/V cells, 
which was prevented by the antiestrogens tamoxifen 
and fulvestrant. Whereas estradiol treatment modestly 
stimulated anchorage-independent colony formation of 
C2-9 and C2-6 cells, neither tamoxifen nor fulvestrant 
prevented the strong colony forming capacity of these cells 
in the presence of estradiol (Figures 7 and 8). Strikingly, 
the FASN inhibitors cerulenin and C75 dose-dependently 
suppressed anchorage-independent colony formation 
when used in combination with tamoxifen or fulvestrant. 
Furthermore, the ability of FASN inhibitors to restore 
the sensitivity of CCN1/CYR61-overexpressing cells to 
Figure 4: CCN1 overexpression up-regulates FASN via activation of the ERK/MAPK pathway. Cells were transiently 
transfected with a plasmid containing a luciferase reporter gene driven by a 178-bp FASN gene promoter fragment harboring a SREBP-
binding site, flanked by auxiliary NF-Y and Sp-1 sites. The next day, cells were treated with graded concentrations of U0126. After 24 h, 
cells were lysed and luciferase activity was measured. Luciferase activity was expressed as relative (fold) change in transcriptional activities 
of FASN promoter-transfected cells in response to U0126 treatments after normalization to pRL-CMV activity. Each experimental value 
represents the mean fold increase (columns) ± S. D. (bars) from at least three separate experiments in which triplicate wells were measured. 
Luciferase activity in U0126-treated cells was compared to that in vehicle-treated control cells. *P < 0.005.
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antiestrogens was extremely effective with the pure anti-
estrogen fulvestrant (Figure 8), which antagonizes the 
hormone-dependent activation of estrogen receptors but 
lacks the mixed antagonist/agonist effects of tamoxifen.
Collectively, these findings reveal that FASN-driven 
endogenous lipogenesis is part of the molecular signaling 
cascade through which CCN1 overexpression promotes 
progression to a metastatic phenotype via acquisition of 
estrogen independence and antiestrogens resistance.
Pharmacological inhibition of FASN activity 
induces higher levels of cellular damage in 
CCN1-overexpressing breast cancer cells
To definitely explore the notion that FASN-driven 
endogenous lipogenesis might constitute an attractive 
therapeutic target for eliminating CCN1-overexpressing 
breast cancer cells, we employed a flow cytometric 
fluorescence-based method to discriminate damaged/
Figure 5: CCN1 overexpression up-regulates FASN via activation of the PI-3K pathway. Cells were transiently transfected 
with a plasmid containing a luciferase reporter gene driven by a 178-bp FASN gene promoter fragment harboring a SREBP-binding site, 
flanked by auxiliary NF-Y and Sp-1 sites. The next day, cells were treated with graded concentrations of LY294002. After 24 h, cells 
were lysed and luciferase activity was measured. Luciferase activity was expressed as relative (fold) change in transcriptional activities of 
FASN promoter-transfected cells in response to LY294002 treatments after normalization to pRL-CMV activity. Each experimental value 
represents the mean fold increase (columns) ± S. D. (bars) from at least three separate experiments in which triplicate wells were measured. 
Luciferase activity in LY294002-treated cells was compared to that in vehicle-treated control cells. *P < 0.005.
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dead from viable cells in immunofluorescently labeled 
populations using propidium iodide (PI) as a dye-
exclusion viability probe. We employed MCF-7 cells 
stably transduced with pBABE-CCN1 or pBABE (empty 
control) retroviral vectors to confirm that CCN1-driven 
FASN overexpression was not due to non-physiological 
CCN1 expression levels in selected clones. When PI 
uptake was plotted against FSC (forward scattering) to 
monitor the response to graded concentrations of C75, 
vector control MCF-7/pBABE cells exhibited a subdued 
Figure 6: Pharmacological inhibition of FASN activity impedes estrogen-independent cell growth of CCN1-
overexpressing breast cancer cells. E2-depleted cells were plated in soft agarose containing E2 (10-9 mol/L), cerulenin (2.5, 5, and 10 
μg/mL), C75 (2.5, 5, and 10 μg/ml), or ethanol (v/v) or DMSO (v/v) vehicle only for 7-10 days. Colony formation (≥ 50 μm) was assessed 
using a colony counter. Each experimental value represents the mean colony number (columns) ± S. D. (bars) from at least three separate 
experiments in which triplicate dishes were counted.
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Figure 7: Pharmacological inhibition of FASN activity reverses tamoxifen resistance of CCN1-overexpressing breast 
cancer cells. E2-depleted cells were plated in soft agarose containing E2 (10-9 mol/L), tamoxifen (10-7 mol/L), cerulenin (2.5, 5, and 10 μg/
mL), C75 (2.5, 5, and 10 μg/ml), their combinations, or ethanol (v/v) or DMSO (v/v) vehicle only for 7-10 days. Colony formation (≥ 50 
μm) was assessed using a colony counter. Each experimental value represents the mean colony number (columns) ± S. D. (bars) from at 
least three separate experiments in which triplicate dishes were counted.
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Figure 8: Pharmacological inhibition of FASN activity reverses fulvestrant resistance of CCN1-overexpressing breast 
cancer cells. E2-depleted cells were plated in soft agarose containing E2 (10-9 mol/L), fulvestrant (10-7 mol/L), cerulenin (2.5, 5, and 10 
μg/mL), C75 (2.5, 5, and 10 μg/ml), their combinations, or ethanol (v/v) or DMSO (v/v) vehicle only for 7-10 days. Colony formation (≥ 
50 μm) was assessed using a colony counter. Each experimental value represents the mean colony number (columns) ± S. D. (bars) from at 
least three separate experiments in which triplicate dishes were counted.
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response with no clear cut dose dependence. Conversely, 
a gradual loss of viability was clearly observed for MCF-
7/CCN1 cells as the C75 concentration was increased 
gradually up to 10 μg/mL (Figure 9).
Because an increase in PI uptake can be viewed 
as a reliable indicator of cell injury severity, our results 
suggest that pharmacological blockade of FASN activity 
causes significantly increased amounts of cellular 
damage in CCN1-overexpressing when compared with 
CCN1-negative breast cancer cells.
DISCUSSION
We reveal for the first time that FASN, a key 
enzyme for endogenous fatty acid biogenesis whose 
overexpression is associated with more aggressive subsets 
of breast carcinomas and poorer clinical outcomes, 
constitutes part of the cellular signaling cascade 
orchestrated by CCN1 to drive breast cancer cell growth, 
angiogenesis and metastatic progression.
In the present study, we show that CCN1 
significantly stimulates FASN gene transcription and 
FASN protein accumulation in breast cancer cells. In 
agreement with earlier reports on the up-regulatory effects 
of androgens, progestins, growth factors, growth factor 
receptors, and hypoxia on FASN gene activity, CCN1-
stimulated FASN expression seems to involve activation 
of the SREBP pathway in breast cancer cells [40-42, 46-
49]. Accordingly, CCN1 overexpression stimulates the 
transcriptional activity of a short and well-defined FASN 
promoter harboring a complex SREBP-binding site, 
whereas its specific deletion completely abolishes the 
stimulatory effects of CCN1. Moreover, the use of various 
inhibitors of different signal transduction pathways 
further reveals that, upstream of SREBP, the effects of 
CCN1 on FASN gene expression are complex and likely 
involve the activation of multiple molecular transducers. 
Consequently, pharmacological blockade of MEK1/MEK2 
and PI-3K activity blunted the up-regulatory effects 
of CCN1 overexpression on FASN gene activity and 
FASN protein accumulation. The results of quantitative 
real-time RT-PCR confirmed CCN1-driven induction of 
FASN through MAPK and PI-3K-mediated pathways, 
as measured by luciferase reporter and immunoblotting 
expression analyses (data not shown). These findings 
strongly suggest that CCN1 overexpression triggers a 
signaling cascade that, up-stream of the FASN gene, links 
the ERK1/ERK2 MAPK and PI-3K transduction pathways 
with SREBP.
That FASN expression becomes activated in 
response to high levels of the angiogenic inducer 
CCN1 together with the finding that the status of 
FASN expression parallels CCN1-regulated secretion 
of the archetypical angiogenic factor VEGF165 might 
counterintuitively suggest that FASN signaling plays an 
active role in CCN1-driven breast cancer angiogenesis, 
a crucial step for metastasis. However, earlier studies 
indeed revealed that cancer cell-associated FASN can 
Figure 9: CCN1 overexpression exacerbates breast cancer cell sensitivity to FASN inhibition. Serum-starved CCN1-
negative MCF-7/pBABE control cells and CCN1-overexpressing MCF-7/CCN1 cells were treated with C75 (0, 5, and 10 μg/mL) for 
2 days. Left panels show the distribution of M1 (PI-negative, undamaged) and M2 (PI-positive, moderately and highly damaged) cell 
populations in the absence/presence of C75. Right panels show the effect of different doses of C75 on undamaged/damaged cell populations 
using a bar-graph representation.
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actively regulate tumor vasculature through altering the 
profile of secreted angiogenic factors including VEGF165, 
and regulation of their bioavailability [50]. Although 
it remains to be determined whether FASN-driven 
lipogenesis might directly participate in the increased 
neovascularization that we previously reported in tumors 
formed by HRG- and CCN1-overexpressing breast 
cancer cells, attenuation of FASN-dependent endogenous 
lipogenesis has been shown to abolish the establishment 
of metastatic colonies without significantly affecting the 
growth of the primary tumor [51]. Remarkably, FASN-
driven enhanced lipid synthesis has been shown to be 
instrumental for the metabolic shift associated with a 
drastic increase in metastatic dissemination following 
cancer adaptation and resistance to antiangiogenic 
treatments [52]. Because pharmacological and genetic 
ablation of FASN overcomes tumor regrowth and 
metastasis after antiangiogenic therapy withdrawal [52], 
it might be worthwhile to evaluate whether the CCN1 Æ 
FASN angiogenesis/lipogenesis axis is responsible for the 
resistance to antiangiogenic therapies [53, 54].
The expression of genes with pro-angiogenic 
ontology including VEGF and, consequently, excessive 
angiogenesis, have been shown to accompany the 
acquisition of estrogen independence and resistance 
to anti-estrogens [55–59]. CCN1 overexpression can 
molecularly substitute for estradiol and foster hormone-
independent growth and resistance to tamoxifen and 
fulvestrant. Thus, our findings showing that FASN 
inhibition blocks anchorage-independent growth of 
CCN1-overexpressing breast cancer cells in the absence 
of estradiol while restoring their responsiveness to 
antiestrogens, strongly suggests that CCN1-driven 
FASN overexpression might be part of the proangiogenic 
phenotype which, if recapitulated in vivo, may promote 
tumor progression. Given that the potential of a cancer 
cell to proliferate and colonize a soft agar environment 
is a surrogate marker of aggressive behavior in vitro 
and indicative of invasion, therapeutic resistance and 
metastatic dissemination, our data identify FASN as a 
potential therapeutic target to improve the efficacy of 
angiogenesis-related development of resistance to anti-
estrogens.
In summary, we present the first evidence that 
overexpression of the metastatic/angiogenic inducer CCN1 
is sufficient to enable a metabolic shift involving FASN-
driven enhanced lipid synthesis in a cell-autonomous 
manner. CCN1-induced preactivation of a metabolic 
infrastructure providing proliferative and survival benefits 
to cancer cells under stressful microenvironmental 
conditions might constitute an efficient preadaptive 
strategy through which CCN1-overexpressing cellular 
states would obtain an advantage in hostile milieus, such 
as those accompanying metastatic dissemination and 
colonization [60]. Because much shorter median time 
from relapse to death remains an urgent unmet need for 
metastatic TNBC patients, the discovery of FASN as 
a novel molecular feature directly involved in CCN1-
promoted breast cancer metastatic progression might 
accelerate the incorporation of new generations of FASN 
inhibitors [61] in the management of metastatic TNBC.
MATERIALS AND METHODS
Materials
Improved Minimal Essential Medium (IMEM) and 
phenol red-free IMEM were from Biofluids (Rockville, 
MD). Fetal bovine serum (FBS) was from Nova-Tech 
Inc. (Grand Island, NY). Dextran-coated charcoal-
treated bovine serum (CCS) was from BioSource 
International (Camarillo, CA). Estradiol (E2) was from 
Sigma-Chemical Co. (St. Louis, MO). Fulvestrant (ICI-
182,780) was a gift from AstraZeneca. LY29400, a 
specific inhibitor of the p110 catalytic subunit of PI-3K, 
and the MEK1/MEK2 inhibitor U0126 were purchased 
from Calbiochem (San Diego, CA), dissolved in 
DMSO, and stored as 10 mmol/L stock solutions in the 
dark at −20 °C until use. Cerulenin and C75 (racemic) 
were purchased from Sigma-Chemical Co. and Alexis 
Biochemicals (San Diego, CA), respectively. Cerulenin 
and C75 were dissolved in DMSO and stored in the dark 
as a stock solution (25 mg/ml) at –20 °C until use. For 
treatments, LY294002, U0126, cerulenin, and C75 were 
freshly prepared from stock solutions and diluted with 
growth medium. Control cells were cultured in medium 
containing the same concentration of DMSO (v/v) as the 
experimental cultures with cerulenin or C75.
The primary antibody (Ab) for FASN 
immunoblotting was a mouse IgG1 FAS monoclonal 
Ab (clone 23) from BD Biosciences Pharmingen (San 
Diego, CA). An anti-β-actin goat polyclonal antibody 
was purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA).
Cell culture
MCF-7 breast cancer cells were obtained from the 
American Type Culture Collection (ATCC) and were 
grown in IMEM supplemented with 5% (v/v) FBS and 2 
mmol/L L-glutamine at 37°C in a humidified atmosphere 
of 95% air and 5% CO2.
MCF-7 cells were engineered to overexpress CCN1 
as described [16, 28]. Briefly, cells were electroporated 
with the eukaryotic expression vector pcDNA3.1/zeocin(-) 
containing the full-length cDNA of human CCN1, or with 
an empty vector as a negative control. Stably transfected 
cells were selected with zeocin (200 μg/ml) for 2 weeks. 
Because CCN1 mRNA and protein expression and cellular 
behavior was similar in most of the clones, a representative 
vector (V3–2) and three clones (C2-2, C2-6 and C2-9) 
were chosen for further analysis.
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To block endogenous CCN1 expression, full-
length CCN1 cDNA was cloned in an antisense 
direction into pcDNA3.1/zeocin(-) and transfected into 
HRG-overexpressing MCF-7/T7 cells, a breast cancer 
progression model developed in our laboratory by 
transfecting full-length HRG-β2 cDNA into non-metastatic 
MCF-7 cells [62, 63]. Several CCN1 antisense (T7/CCN1-
AS) clones were isolated and the presence of antisense 
CCN1 mRNA was confirmed by RNAse protection assay. 
We also generated multiple clones of vector-transfected 
MCF-7/T7 (T7/AC-V) cells, and all behaved similarly 
to the wild-type MCF-7/T7 clone. Four T7/CYR61-AS 
clones (T7/CCN1-AS2, T7/CCN1-AS4, T7/CCN1-AS6, 
and T7/CCN1-AS7) and one vector clone (T7/AC-V1) 
were chosen for further analysis. CCN1-overexpressing 
MCF-7 clones and CCN1-AS MCF-/T7 clones were 
grown as described, except than 200 μg/ml of zeocin was 
added to the culture medium.
A pool MCF-7/CCN1 cell line was generated by 
transducing MCF-7 cells with a retroviral vector (pBABE) 
containing the full-length cDNA for CCN1. Cell lines 
were selected with puromycin (3 μg/mL) (MCF-7/CCN1), 
and a control cell line was generated in parallel, under 
similar conditions using the empty retroviral vector (MCF-
7/pBABE) alone.
FASN promoter luciferase assays
Cells were transfected with FuGENE 6 (Roche 
Biochemicals, Indianapolis, IN). Overnight serum-
starved cells seeded into 24-well plates (5 × 104 cells/
well) were transfected for 18 h in low-serum (0.1% 
FBS) medium with 300 ng/well of the pGL3-luciferase 
(Promega, Madison, WI) vector containing a luciferase 
reporter gene cloned downstream of an intact (FASN 
wtSREBP-BS-Luc) 178-bp FASN promoter fragment, 
and pRL-CMV (30 ng/well), which was used to correct 
for transfection efficiency. Transfected cells were washed 
and incubated with/without graded concentrations of 
U0126 or LY294002. Approximately 24 h after treatments, 
luciferase activity from cell extracts was detected using 
the Luciferase Assay System (Promega, Madison, WI) 
according to the protocol specified by the manufacturer 
using a VICTOR2™ 1420 Multilabel Counter (Perkin 
Elmer™). The level of activation in FASN promoter-
transfected cells was determined after normalization 
to the luciferase activity in cells co-transfected with 
equivalent amounts of the empty pGL3-luciferase vector 
lacking the FAS promoter (Ø-Luc) and the internal control 
plasmid pRL-CMV, which was taken as 1.0-fold. This 
control value was used to calculate the fold change in 
transcriptional activities of FASN promoter- transfected 
cells in response to either CNN1/CYR61 overexpression 
or U0126/LY294002 treatments after normalization to 
pRL-CMV activity.
Immunoblotting analysis of FASN
Cells were washed twice with PBS and lysed 
in a buffer (20 mmol/L Tris (pH 7.5), 150 mmol/L 
NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1% Triton 
X-100, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L 
β-glycerolphosphate, 1 mmol/L Na3VO4, 1 μg/mL 
leupeptin, 1 mmol/L phenylmethylsufonylfluoride) for 
30 min on ice. Lysates were cleared by centrifugation in 
an Eppendorff tube (15 min at 14 000 × g, 4°C). Protein 
content was determined against a standardized control 
using the Pierce Protein kit (Rockford, IL). Equal amounts 
of protein were diluted in 5× Laemmli sample buffer, 
heated for 10 min at 70°C, subjected to electrophoresis 
on 3–8% NuPAGE Tris-Acetate gels and transferred to 
nitrocellulose membranes. Non-specific binding was 
minimized by blocking for 1 h at room temperature 
with TBS-T (25 mM Tris-HCl pH 7.5, 150 mM NaCl 
and 0.05% Tween-20) containing 5% (w/v) non-fat dry 
milk. Filters were washed in TBS-T and incubated with 
primary antibodies for 2 h at room temperature in TBS-T 
containing 5% (w/v) non-fat dry milk. Membranes were 
washed in TBS-T, horseradish peroxidase-conjugated 
secondary antibodies in TBS-T were added for 45 min, 
and immunoreactive bands were detected by the enhanced 
chemiluminiscence reagent (Pierce, Rockford, IL). Blots 
were re-probed with an antibody for β-actin. Densitometric 
values of protein bands were quantified using Scion 
Imaging Software (Scion Corp., Frederick, MD).
In situ immunofluorescent staining of FASN
Cells were seeded at 1 × 104 cells/well in a four-
well chamber slide (Nalge Nunc International, Rochester, 
NY). After 48 h incubation with graded concentrations of 
U0126 or LY294002, cells were washed with PBS, fixed 
in 4% paraformaldehyde in PBS for 10 min, permeabilized 
with 0.2% Triton X-100/PBS for 15 min, and stored 
overnight at 4°C with 10% horse serum in PBS. The cells 
were washed and then incubated for 2 h with an anti-
FASN mouse monoclonal antibody diluted 1:200 in 0.05% 
Triton X-100/PBS. After extensive washes, the cells were 
incubated for 45 min with FITC-conjugated anti-mouse 
IgG secondary antibody (Jackson ImmunoResearch 
Labs, West Grove, PA) diluted 1:200 in 0.05% Triton 
X-100/PBS. The cells were washed five times with PBS 
and mounted with VECTASHIELD + DAPI (Vector 
Laboratories, Burlingame, CA). As controls, cells were 
stained with primary or secondary antibody alone. No 
significant fluorescence was found in control experiments 
(data not shown). Indirect immunofluorescence was 
recorded on a Zeiss microscope. Images were noise-
filtered, corrected for background, and prepared using 
Adobe Photoshop.
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Soft agar colony formation assays
Cells were grown in phenol red-free IMEM 
and 5% CCS for 5 days in T-75 flasks to deplete E2. 
A bottom layer of 1 mL IMEM containing 0.6% agar 
and 10% CCS was prepared in 35-mm multi-well cluster 
dishes. After the bottom layer solidified, cells (20,000/
dish) were added in a 1 ml top layer containing either 
E2, ICI-182,780, cerulenin, C75, combinations thereof, 
ethanol (v/v), or DMSO (v/v), and 10% CCS. Dishes 
were incubated in a humidified 5% CO2 incubator at 
37 °C, and colonies measuring ≥ 50 μm were counted 
after ~ 14 days using a cell colony counter after staining 
with nitroblue tetrazolium (Sigma). Assays were carried 
out in triplicate.
ELISA of secreted VEGF
Cell lines were seeded in 100-mm plates and 
cultured in complete growth medium. After reaching 
~75 % confluence, the cells were washed twice with 
pre-warmed PBS and cultured in serum-free medium 
overnight. Cells were cultured in 0.1 % FBS-IMEM 
at 37 °C for up to 48 h. After this time, the conditioned 
medium was aspirated, cleared by centrifugation at 
1100 × g for 10 min at 4 °C, and stored at −80 °C until 
analysis. VEGF protein levels in conditioned media 
were determined by a VEGF ELISA (R & D Systems, 
Minneapolis, MN), as per the manufacturer’s instructions.
Cellular viability assessment using propidium 
iodide dye
Propidium iodide (PI) is a membrane impermeant 
DNA dye that is generally excluded from viable cells. 
After treatment with C75 (48 h), the cells were washed 
in cold PBS + 1% FBS and incubated with RNAse A 
(0.2 mg/mL) in PBS at 37 °C for 20 min. PI was added 
to the cell suspension to reach a concentration of 20 μg/
mL in PBS. The cells were then incubated for a further 
30 min in the darkness at room temperature. The cells 
were then analyzed in a FACScalibur flow cytometer 
(Becton Dickinson, San Jose, CA). CellQuest software 
(Becton Dickinson) was run for data acquisition and 
analysis.
Statistical analysis
All observations were confirmed by at least three 
independent experiments. Data are presented as means 
± S.D. Student’s t test (paired and unpaired) was used 
to evaluate the statistical significance of mean values 
(two tailed). Statistical significance level was P < 0.005 
(denoted as *).
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